Trials / Completed
CompletedNCT00642707
Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
A Phase 2a, Randomized, Double-blind, Placebo Controlled Study of PRO 140 by Subcutaneous Administration in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- CytoDyn, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is: 1. To assess the antiviral activity of PRO 140 2. To assess the safety and tolerability of PRO 140 3. To generate additional PK, PD and safety data of PRO 140
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRO 140 (humanized monoclonal antibody to CCR5) | |
| DRUG | Placebo Comparator |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2008-03-25
- Last updated
- 2016-01-14
- Results posted
- 2013-05-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00642707. Inclusion in this directory is not an endorsement.